Introduction
and is associated with gene silencing in conjunction with histone core modifications, probably through chromatin remodelling [7] [8] [9] . Several findings support the premise that hypomethylation of the DNA surrounding the promoter region is a prerequisite for gene activation, whereas heavy methylation leads to gene silencing [10] .
Methyl-CpG-binding proteins (e.g. MeCP2) bind preferentially to methylated DNA. MeCP2 is closely related to Rett syndrome, a neurodevelopmental disorder associated with onset of cognitive and motor deterioration at 6-18 months of life [11] . The Xlinked MECP2 gene encoding the MeCP2 has mutations in about 80% of classical Rett syndrome patients [12] . MeCP2 recruits a corepressor complex containing Sin3 and histone deacetylase (HDAC) [8, 13] , modifying chromatin behaviour and silencing transcriptional activity [14] . MeCP2 is also involved with histone methyltransferase activity [15] and the DNA methyltransferase Dnmt1 [16] .
Nucleosome structure regulates the interaction of DNA with most nuclear factors. Chromatin accessibility is a key regulatory step in transcription, replication, DNA repair and recombination. The nuclear factor's accessibility to DNA can be regulated by different ATP-dependent chromatin-remodelling complexes, which alter DNA-histone contacts by using the energy of ATP hydrolysis [17] . The SWI/SNF family is a well-characterized class of ATPdependent chromatin-remodelling complexes and is conserved from yeast to human [18] . It disrupts nucleosome structure, increases DNA accessibility and is associated with transcriptional activity [19] . In yeast, SWI/SNF is a large (2 MDa) assembly [20] composed of Brm, Brg1, INI1 and BAF subunits [21] and is highly conserved in eukaryotes. SWI/SNF remodelling can regulate transcription in either direction.
It was reported recently that MeCP2 interacted with a chromatin-remodelling factor (Brm) [22] , but a later report presented contradictory results [23] . In the present study, we examine the interaction of MeCP2 with chromatin-remodelling factors. MOR shows unique spatial patterns of expression the brain. To achieve such patterns, the expression of MOR must be strictly regulated. In previous studies, we showed that MOR transcription could be regulated epigenetically in several in vitro cell models. In the present study, we show that MOR mRNA levels in several brain regions can be regulated by epigenetic modifications in the MOR promoter region.
Methods and materials
Cell culture NS20Y cells were cultured in DMEM supplemented with 10% FBS. Methods for P19 cell culture and differentiation have been described previously [24, 25] . Treatments with 5Ј-aza-2Ј-deoxycytidine Sigma) and trichostatin A (TSA; Sigma, St. Louis, MO, USA) and cell harvesting for RNA determination were performed as described previously [25] . 
Dissection of brain regions and preparation of total RNA

RNA isolation from laser capture microdissection (LCM) samples
Brains from C57BL6/129Ola mice were snap-frozen in liquid nitrogen and embedded in Tissue-Tek O.C.T. (Sakura Finetek). Serial sections, 10 m in thickness, were mounted on Superfrost Plus (Fisher Scientific, Pittsburgh, PA, USA). LCM samples were prepared according to the manufacturer's (Arcturus Engineering) instructions, optimized for preparing and staining LCM samples from frozen tissue. Cryostat sections for LCM were transferred from storage at -80ЊC and immediately immersed in 75% ethanol at room temperature for 30 sec. Slides were rinsed in H2O, washed in 75%, 95% and 100% ethanol for 30 sec. each and in xylene for 5 min. Slides were air-dried in a laminar flow hood for 5 min. and immediately processed for LCM. LCM was repeated at least three times for each sample and performed with a PixCell II Microscope (Arcturus Engineering) using a 60 mW laser with a 7.5-m beam at 100-200 mV. Samples of RNA were prepared from 200-400 brain cells (one laser pulse equals approximately one cell). Total RNAs were isolated from the captured LCM cells using TRI reagent (Molecular Research Center, Cincinnati, OH, USA).
RT-PCR and real-time quantitative RT-PCR
Total RNA was isolated using TRI reagent and analysed by RT-PCR using MOR gene-specific primers [25, 26] Table 1 ). Similar reactions were performed with primers for ␤-actin as an internal control [25] . Primers for the neuronal cell marker neurofilament H (NF-H) and glial fibrillary acidic protein (GFAP) have been described previously [25, 27] 
. RT-PCR was performed with a QIA-GEN OneStep RT-PCR kit (QIAGEN, Hilden, Germany) and MOR PCR primers (see
Coimmunoprecipitation and Western blot analysis
Procedures for coimmunoprecipitation and Western blots were performed as described [32] . 
Chromatin immunoprecipitation assay (ChIP)
ChIPs were performed by using a modified protocol from Upstate as reported previously [25, 33, 34] 
Results
mRNA expression of MOR gene and promoter methylation status
We reported previously [25] (-569, -388 and -344) in the PP were highly methylated (Ͼ73%), whereas other sites were less so (Fig. 1C) . Interestingly, higher levels of methylation were observed downstream from the PP transcription initiation site (ppTIS) in NS20Y cells (Fig. 1C) relative to P19 cells (both normal and differentiated) or from mouse brain [25] , which showed almost no methylation in the region (see also Fig. 1B ; -182 and -178 sites). (Fig. 1A) (Fig. 2C ). These data suggest that epigenetic mechanisms, such as DNA methylation or histone modification, are involved in MOR gene silencing.
Expression profiles of two MOR transcripts in various cells types and in mouse brain, along with the methylation status of their MOR gene promoters
We examined the expression profiles of two MOR transcripts in various cell types and in mouse brain. Using real-time qRT-PCR
DNA methylation and histone modification of the MOR promoter are associated with MOR gene transcription
To investigate whether induction of the MOR gene is mediated by DNA methylation or chromatin modification, we treated NS20Y cells with an inhibitor of DNA methylation (5-aza-dC) and a HDAC inhibitor (TSA). Both drugs up-regulated MOR expression in the cells (Fig. 2). Samples treated with as little as 2 M 5-aza-dC for 3 days showed increased PP-MOR transcripts. Cells treated with 300 nM TSA for 24 hrs also showed an increase in the expression of the PP transcript (Fig. 2A). Similar inductions of the minor DP transcript were observed in both 5-aza-dC-and TSA-treated samples (Fig. 2B). Combined treatment with 100 nM TSA and 1-2 M 5-aza-dC resulted in enhanced induction of PP-MOR transcript
Analysis of methylation status by methylation-sensitive restriction enzyme assay
Repression of MOR expression in NS20Y cells was alleviated by 5-aza-dC treatment (Fig. 2). Thus, it was important to determine whether the methylation state of the MOR gene promoter could be changed in NS20Y cells treated with 5-aza-dC. The bisulphite technique for methylation analysis is laborious and timeconsuming when multiple samples are to be analysed. We therefore developed a methylation-sensitive restriction enzyme assay for methylation analysis of both promoter regions. Although the new method is limited only to CpG sites containing the corresponding restriction enzyme recognition region, it provides an efficient means for analysing several samples in a shorter time and with less work. Briefly, sodium bisulphite is used to convert all unmethylated cytosine nucleotides to thymidine; methylation-specific PCR is then performed. The CpG site is then digested with a methylationsensitive restriction enzyme (e.g. Hpy188I) that cleaves only at the methylated CpG sites (in this case, -569). Agarose gel
Fig. 1 Expression of the -opioid receptor (MOR) gene in mouse neuronal cells at different stages of development and in the mouse brain, along with levels of CpG DNA methylation in the MOR promoters. (A). Expression of the MOR gene in the indicated cell types and in whole mouse brain analysed by real-time quantitative RT-PCR (qRT-PCR). PP mRNA: proximal promoter (PP)-derived MOR transcripts; distal promoter (DP) mRNA: DP-derived MOR transcripts. Levels of MOR mRNA were determined in normal (i.e. undifferentiated; P19), intermediate (AP2d) and fully differentiated (AP4d) P19 cells, neuroblastoma cells (NS20Y), and whole mouse brain (MB). The primers used were MOR_E3-S and MOR_E4-AS for PP mRNA and S-408
and AS-285 for DP mRNA (see Table 1 ). [36] . dpTIS: transcription initiation site of the DP [46] . (Fig. 2) . Similar experiments performed for the -182 and -178/-170 sites using Hpy188I and HpyCH4IV likewise showed reduced methylation after 5-aza-dC treatment. To confirm these results, standard DNA sequencing was performed on each PCR product pool (Fig. 3C) . Two CpG sites (-569 and -434) showed reduced methylation after 5-aza-dC treatment. The CpG site -1601 (recognized by ClaI) in the upstream region of the DP was also demethylated by 5-aza-dC (Supporting Fig. 1) , coincident with increased DP-MOR expression (Fig. 2) .
electrophoresis revealed both the cleaved shorter band and a band representing the undigested original PCR product. The ratio of the intensity of the undigested band to the digested band increased with 5-aza-dC treatment in a dose-dependent manner (Fig. 3). P19 cells (undifferentiated and fully differentiated) and mouse brain were included as controls. The corresponding methylation percentages revealed that the methylated PP was demethylated in the presence of 5-aza-dC (Fig. 3B). This correlates with the MOR mRNA induction observed by treatment with 5-aza-dC
Differential expression of PP and DP transcripts in regions dissected from mouse brain
To understand the epigenetic mechanisms regulating the MOR gene in vivo, we first analysed MOR mRNA expression in tissues dissected from specific regions of the mouse brain. Nine such regions (Fig. 4D) (Fig. 4B) . In contrast, PP transcripts (Fig. 4A) showed a quite different expression profile. Highest expression of PP was observed in midbrain, followed by hypothalamus and lower levels in the cerebellum, both the frontal and posterior cortices, and hippocampus. This PP transcript pattern was similar to that reported previously [3] . In order to assure that brain tissue microdissections were performed properly, we used neuron-and astrocyte-specific markers for RT-PCR analyses (Fig. 4E) . Genes specific for each cell type were present in all brain regions examined, but the ratios differed between regions, suggesting that the corresponding cell types were distributed differentially in the microdissected tissues.
For a more defined analysis of specific brain regions, we used LCM to isolate each brain region. The images (Fig. 5A) (Fig. 5C ). The expression of the astrocyte-specific GFAP was very similar to the results seen in microdissected tissues (Fig. 4E) 5) . Primers for ␤-actin were used as internal controls (see Table 1 ).
Mtap2 are specific for neuroal cells, the expression profiles for these genes differed between the microdissected samples (Fig. 4E) and the LCM-derived tissues (Fig. 5C) (Fig. 6 ). This pattern correlates inversely with the levels of PP expression (Fig. 4A) Methylation analyses were similarly performed for the DP region ( Fig. 6C and D) . Three CpG sites (-1601, -1545 and -1466) were analysed based on the availability of restriction enzyme recognition sites. However, the methylation patterns did not appear to correlate with mRNA expression levels in tested regions. We therefore decided to analyse all the CpG sites in DP-MOR from four tissues (olfactory bulb, striatum, hypothalamus and cerebellum) for methylation using sodium bisulphite conversion and DNA sequencing (Fig. 6E) Fig. 1 ) correlated with DP-MOR mRNA expression levels in NS20Y cells (Fig. 2B) (Fig. 7B) . [36] showed slight regional differences (Fig. 7A) . As a negative control, we performed ChIP assays with ␤-actin, which is actively expressed in all brain regions, independent of methylation of its regulatory region. MeCP2 was not associated with the ␤-actin gene (Fig. 7A) .
. Overall, CpG sites in the DP were hypermethylated, except for three sites: -999, -980 (ranging from 30% to 70% methylation) and -1245 (no methylation). Although forced demethylation induced by 5-aza-dC (see Supporting
(B) -PCR products (Full-A and Full-B fragments) from NS20Y cells treated with the indicated concentrations of 5-aza-dC, as well as from undifferentiated P19 cells, fully differentiated P19 cells (AP4d), and mouse brain (MB). Intact PCR product (no RE) was used as a control. The graphs to the right of each gel show the percentage of methylation, determined by comparing the intensity of the bands cut by Hp1 or Hp4 relative to the intensity of the unmethylated (i.e. upper, uncut bands). Column numbers in graph indicate the corresponding gel lanes. Data for the graphs are the mean Ϯ S.E.M. from three independent experiments. *Indicates P Ͻ 0.05 compared with no 5-aza-dC-treated samples. (C) -Methylation analyses of MOR promoter by automated authentic DNA sequencing. Methylation percentages on two CpG sites (-569 and -434) from the Full-A methylation-specific PCR product were reduced by 5-aza-dC treatment. most of the regions remained elevated even as the DP-MOR mRNA levels differed.
Interaction of MeCP2 with the MOR promoter is increased in the cerebellum
Direct binding of specific methyl-CpG-binding proteins to methylated DNA is a major mechanism of methylation-induced transcriptional repression [35]. We examined whether the differential MOR transcription levels in dissected brain regions correlated with the methylation of the MOR promoter and/or greater affinity for methyl-CpG-binding proteins. We used a ChIP assay with realtime qPCR to investigate the association of endogenous MeCP2 with MOR promoters (Fig. 7A). The highest levels of PP-MOR association with MeCP2 occurred in the cerebellum. This was consistent with the methylation status (Fig. 6B) and levels of MOR expression in the cerebellum (Figs. 4A and 5B). This represents specific binding of MeCP2 with the MOR promoter, because normal rabbit serum and a non-specific antibody (anti-gal4) failed to immunoprecipitate MOR promoter sequences
Also, the release of MeCP2 was specific to the MOR promoter, because the interaction of MeCP2 with the imprinted gene H19
The specificity of the antibodies against MeCP2 and the expression levels were shown by Western blotting (Fig. 7C) . (Fig.  7C) , with the highest levels in the cerebellum, followed by the olfactory bulb, hypothalamus and posterior cortex; lowest levels of protein expression occurred in the striatum. Because ␤-actin also showed some degree of differential expression in different brain regions, two neuronal-specific markers (␤III-tubulin and N-cadherin) were used to normalize protein loading. Both proteins were detected at similar densities in all brain regions (Fig. 7C,  lanes 1 [8, 13, 15] . ChIP analyses with realtime qPCR revealed that a MOR promoter-associated histone (H3) in the primer PP region (overlapping the PP) was methylated at lysine 9 (H3 dm K9; Fig. 7B ) in the olfactory bulb and cerebellum. This modification on the H19 gene correlates with gene inactivation [37] and is facilitated by MeCP2 [15] . Furthermore (Fig. 7B) . However, the lowest levels of acetylated histone H3 occurred in the cerebellum. Acetylated histone H4 was detected at highest levels in the hypothalamus (consistent with this region expressing more PP-MOR transcript than other regions; Figs 4A and 5B). This suggests that for MOR activation in brain, histones H3 and H4 must be hyperacetylated and H4 hyperacetylation is differentially and uniquely localized to specific brain regions (Fig. 7B) . (Fig. 8) Fig. 1D . dpTIS: transcription initiation site of the MOR DP. Methylation-specific PCR was performed with primers MS-1754 and MAS-927 (see Table 1 ) followed by TA cloning (Invitrogen). The percentages of methyl CpG versus unmethylated CpG are indicated for all CpG sites.
MeCP2 was expressed differentially in various brain regions
-5). Cells from intermediate (AP2d) and fully differentiated (AP4d) P19 cells also showed expression of the two proteins, whereas little or no expression was seen in NS20Y or undifferentiated P19 cells (lanes 6 and 7).
Fig. 4 Differential expression of the PP-and distal promoter (DP)-transcripts in regions microdissected from mouse brain. (A) and (B). Mouse brains were dissected into different regions (as shown in Fig. 4D) for the epigenetic study of MOR gene expression: olfactory bulb (OB), striatum (STM), hippocampus (HPC), hypothalamus (HPT), midbrain (MidB), Pons/Medulla (Po/Me), cerebellum (CRB), frontal cortex (FCX), posterior cortex (PCX), spinal cord (SPC). NS20Y cells were used as the MOR-negative control. To reduce PCR errors, two PCR primer sets (PP1 and PP2 for PP-MOR, DP1 and DP2 for DP-MOR; see Table 1) amplifying from different locations for each transcript were used for RT-PCR. For real-time qRT-PCR, only one set of PCR primers was used for each transcript (MOR_E3-S and MOR_E4-AS for PP-MOR, S-408 and AS-285 for DP-MOR). (C) -Results of RT-PCR and realtime qRT-PCR using ␤-actin primers (Table 1). (D)-Diagram of mouse brain regions (sagittal view) included in this study. Dissected regions from two to three brains were pooled for the indicated experiments. At least three different dissections were performed separately to repeat the RT-PCR and realtime qRT-PCR experiments. Data shown for real-time qRT-PCR are mean Ϯ S.E.M. from the three independent experiments. (E) -Expression of neuronal cell marker [27] neurofilament H (NF-H) and astrocyte marker glial fibrillary acidic protein (GFAP) genes in microdissected brain regions analysed by RT-PCR. Primers for NF-H and GFAP [25] were used for RT-PCR. NS20Y cells and samples with no added RT enzyme were used as negative controls. The intensities of the bands are expressed graphically (right), and the ratio of GFAP to NF-H expression is indicated under the gels.
MOR activation/silencing correlates with histone modifications in brain regions
We examined the possibility that MeCP2 might regulate MOR promoter activation by altering the chromatin architecture of the MOR gene in brain tissue. MeCP2 mediates long-term gene silencing in part by recruiting histone-modifying enzymes such as deacetylases and methyltransferases
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Fig. 5 Differential expression of the MOR gene in laser capture microdissection (LCM) brain samples. (A)-Dissected regions (frontal cortex, posterior cortex, and hippocampus) from mouse brain tissue sections are shown before and after sampling, along with captured samples (Cap). (B)-Expression patterns of PP-MOR in specific microdissected brain regions, as determined by RT-PCR using the primers MOR-S1 and MOR-AS1. The results of the real-time qRT-PCR from LCM brain and spinal cord samples are shown graphically below the RT-PCR data. NS20Y cells were included as a control. (C)-Expression of cell type-specific marker genes in brain regions prepared by LCM were analysed by real-time qRT-PCR using PCR primers (Table 1) for glial fibrillary acidic protein (astrocytes), integrin-␣ M (Itgam; microglia), and microtubule-associated protein 2 (Mtap2; neuronal cells). NS20Y cells were used as a negative control. The results are expressed as described above for the MOR gene.
MeCP2 interacts with chromatin remodelling factor Brg1 and is involved in epigenetic programming of the MOR gene
Because different interactions with MeCP2 and chromatin modifications were observed in different brain regions, we sought to determine if these correlated with the dissociation or association of chromatin-remodelling factors such as Brg1 or Brahma (Brm)
Fig. 6 Restriction enzyme (RE)-assisted methylation analysis of the proximal MOR promoter from dissected mouse brain regions. Analyses were performed as described for Fig. 3, except as indicated. (A) -For the -569 CpG site, methylation-specific PCR products were amplified using MS-630 and MAS-180 primers (Table 1), generating the Full-A fragment. Hp1 was used to cut the amplified PCR products. For the -182 and -178/-170 sites, PCR amplification was performed with the MS-376 and MAS-79 primers (Full-B) and samples were digested with either Hp1 or Hp4, respectively. (B) -Methylation-specific PCR products from various regions of the mouse brain. The demethylation of the MOR promoter is expressed graphically below the gel as the mean Ϯ S.E.M. (C) and (D) -RE-assisted methylation analysis of the MOR DP from dissected mouse brain regions. Methylation-specific PCR products were amplified using MS-1754 and MAS-927 primers (Table 1) generating the Full fragment. Several Restriction enzymes (ClaI, BstBI, and HpyCH4IV) were used to detect methylation status, as indicated. The analyses and quantification of methylation were performed as described above. (E) -Methylation status of the DP of the MOR gene in mouse brain regions (olfactory bulb, striatum, hypothalamus, and cerebellum). Except as noted below, experiments were performed as described for
Fig. 7 Chromatin immunoprecipitation (ChIP) analysis by real-time qPCR for chromatin modification and MeCP2 interaction. (A) -Primers specific for the MOR PP (S-408 and AS-285),
␤-actin, and H19 promoter [36] were used to amplify genomic DNA sequences present in each immunoprecipitate by real-time qPCR.
Recruitment of MeCP2 to the MOR gene promoter was dramatically increased in the cerebellum (CRB). (B) -Amplification of soluble chromatin before precipitation was used as an input control. Amplification for each antibody was normalized against its input after calculating individual amounts from the real-time qPCR reaction, based on each standard curve (see section 'Methods and materials' for details). Parallel controls included ChIP performed without antibody, or nonspecific antibody (anti-gal4). (C) -The expression of MeCP2 was assessed by Western blot analysis using MeCP2 antibody in various brain regions, as well as normal (P19), partially (AP2d) and fully differentiated (AP4d) P19 cells. MeCP2 protein levels in neuroblastoma NS20Y cells are also shown. Anti-␤-actin was used as a control. Two neuron-specific antibodies (␤III-tubulin and N-cadherin) were used to show the integrity of cells and brain tissues.
controls (Fig. 8A) . Likewise, when MeCP2 antibody was used for immunoprecipitation, the Brm band was not detected on Western blots, relative to input or SN controls. MeCP2 interacts with the transcriptional repressor mSin3A for transcriptional silencing [13] . As a control, the MeCP2 antibody was able to successfully pull down the mSin3A protein (Fig. 8A) .
Surprisingly, Brg1 (another component of the ATPase subunits of the mammalian SWI/SNF complex) was associated with
MeCP2 protein (Fig. 8A) as both full-length Brg1 and its isoforms, although the isoforms showed weaker interactions. Indeed, Western blots performed with the same Brg1 antibody as that used in the coimmunoprecipitation experiments showed Brg1 expression in different cells and mouse brain (Fig. 8B) . Taken together, these results indicate that the MeCP2 repressor complex is associated with Brg1 rather than Brm, possibly because of a higher binding affinity for Brg1. (Fig. 4A) . Likewise, the lower expression of PP-MOR in the olfactory bulb and cerebellum correlated with the decreased Brg1 interaction in the PP-MOR. These data suggest that the chromatin-remodelling factor Brg1 might be involved in PP-MOR activation in brain tissue in vivo. In contrast, there appeared to be no correlation between Brg1 interaction and DP-MOR expression in the tissues tested (Figs. 5B and 8C) . (Fig. 8D) [16] , suggesting that Dnmt1 associates with MeCP2 to perform maintenance methylation in vivo. We performed ReChIP on specific regions of the mouse brain using Dnmt1 antibody followed by MeCP2 antibody (Fig. 8D) (Fig. 1) (Fig. 4) [46] ; these differences were confirmed in the present study (Fig. 1A) . Although the in vivo levels of PP-derived transcripts are much higher than those of transcripts derived from the DP, it is possible that the translation efficiency of the two transcripts is also different, as reported recently [28] (Fig. 6) . These data suggest that in the mouse brain, the expression of PP-MOR might be controlled by DNA methylation and its associated mechanisms at the PP-promoter, but that this is not the case for the DP-MOR.
Using the Brg1 antibody, ChIP analyses assisted with realtime qPCR were performed with dissected brain samples and NS20Y cells to show the effect of endogenous Brg1 on MOR promoter (Fig. 8C). For the PP-MOR region, enhanced interactions with Brg1 were observed in the hypothalamus and posterior cortex, and somewhat less so in the striatum. Lower levels of Brg1 interaction occurred in the cerebellum and olfactory bulb, and NS20Y cells. The enhanced Brg1 interaction on the PP-MOR region from the hypothalamus and striatum correlated with the high levels of PP-MOR expression
As described above, MeCP2 interacts with Brg1, and the Brg1 was localized to PP-MOR derived from the hypothalamus and striatum containing enhanced MOR expression and hypomethylated PP-MOR promoter. However, the MeCP2 interactions on the PP-MOR from these two regions were very low compared to cerebellum tissue. To resolve this apparent contradiction, we performed ReChIP experiments using antibodies against Brg1 and MeCP2. When PP-MOR was used as the primer, anti-Brg1 as the first antibody and anti-MeCP2 as the second antibody, the high levels of Brg1 interaction in the hypothalamus did not coincide with similar levels of MeCP2 interaction, even though MeCP2 levels in the hypothalamus were slightly higher than those in other tissues
Higher levels of histone acetylation on H3 and H4 were observed in the hypothalamus, which expressed higher levels of MOR than did four other tested regions (Fig. 7) (Fig. 7A) . In our previous report [25] One research group [22] recently reported that MeCP2 interacted with an ATP-dependent chromatin-remodelling factor (Brm), but a later report presented contradictory results [23] . In coimmunoprecipitation experiments (Fig. 8A) 
